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Cerebrovascular disease is the third leading cause of death and the leading cause of disability in Cuba and in several developed
countries. A possible neuroprotective agent is the rHu-EPO, whose eﬀects have been demonstrated in models of brain ischemia.
The Neuro-EPO is a derivative of the rHu-EPO that avoids the stimulation of erythropoiesis. The aim of this study was to
determine the Neuro-EPO delivery into the central nervous system (CNS) to exert a neuroprotective eﬀect in cerebral ischemia
model of the Mongolian gerbil. The Neuro-EPO in a rate of 249.4UI every 8hours for 4days showed 25% higher viability eﬃcacy
(P>0.01), improving neurological score and behavior of the spontaneous exploratory activity, the preservation of CA3 areas of
the hippocampus, the cortex, and thalamic nuclei in the focal ischemia model of the Mongolian gerbil. In summary, this study,
the average dose-used Neuro-EPO (249.4UI/10µL/every 8hours for 4days), proved to be valid indicators of viability, neurological
status, and spontaneous exploratory activity, being signiﬁcantly lower than that reported for the systemically use of the rHu-EPO
as a neuroprotectant. Indeed, up to 12h after brain ischemia is very positive Neuro-EPO administration by the nasal route as a
candidate for neuroprotection.
1.Introduction
Till now, there is not a drug suﬃciently eﬀective, speciﬁc,
and of safe access to the central nervous system (CNS) that
could be used as a neuroprotectant in stroke in acute or
chronic stage. Furthermore, most eﬀective neuroprotective
therapeutic agents with positive preclinical results in brain
ischemia animals models are not tolerated clinically [1,
2]. To use the same molecules that are expressed in the
brain after the stroke [3] helping to the endogenous brain
protection, may be our strategy for ﬁnding a solution to this
diﬃculty. One of these molecules is the recombinant human
erythropoietin (EPO). Recombinant variant (rHu-EPO) has
been evaluated for these purposes in diﬀerent models of
stroke such as in mouse, rat, gerbil, and rabbit, including
global and focal cerebral ischemia [4–9], where it has shown
convincing neuroprotective eﬀect.
Although the neuroprotective mechanism of rHu-EPO is
stillinvestigated,ithasbeenarguedthatitsactionismediated
by receptors found on the walls of vascular endothelium
and in astrocytes [10, 11]. The mechanisms of rHu-EPO
as a neuroprotective agent appear to be multifactor. The
rHu-EPO can indirectly mediate as neuroprotectant on the
restoration of blood supply to tissue damage or acts directly
on neurons by activation of several molecular signaling
pathways [12].2 The Scientiﬁc World Journal
The neuroprotective eﬀects of rHu-EPO may be pro-
duced by diﬀerent factors within that included: the antag-
onism of glutamate-induced cytotoxicity, the increased
expression of antioxidant enzymes, the decrease of the
formation of nitric oxide (NO)-mediated free radicals [13],
the normalization of cerebral blood ﬂow [14], the inﬂuence
neurotransmitter release, the promotion of angiogenesis [15,
16], the inhibition of apoptosis induced by excitotoxins
and nitric oxide, the increased expression of antiapoptotic
genes, the neurotrophic eﬀect, the decrease of the neuronal
excitability, the cerebral anti-inﬂammatory eﬀect, the inhibi-
tion of kainate-induced apoptosis and the pro-inﬂammatory
cytokine production, and the neurogenic and angiogenic
eﬀect that contributes to ischemic preconditioning; all
together can justify the use of rHu-EPO in the treatment of
cerebrovascular, neurodegenerative, and psychiatric diseases
[15, 17].
The organs with narrow endothelial barriers, as the
CNS, generally exclude polar and high-weight molecules
[18, 19]. However, for certain proteins, a transit mechanism
mediatedbyreceptors,suchastransferrin,insulin,andleptin
has been established [20]. This same mechanism has been
proposed to explain the brain delivery of the rHu-EPO
applied intravenously. This hypothesis is based primarily on
the fact that rHu-EPOA administered systemically can be
detected in the CSF of rats, sheep, and monkeys in neu-
roprotective concentrations, with a delay of, approximately,
60 minutes [21–24]. Second, immunohistochemical studies
havedemonstratedahighdensityofEPO-Raroundthebrain
capillaries, manly in astrocytes feet and on the luminal side
of the capillary endothelial cells [6, 25].
Repeated administration of rHu-EPO high doses can
activate the hematopoietic process with the potential risk of
increasing blood viscosity, which might worsen the outcome
after stroke either because of hematocrit elevation or other
negative eﬀects [26]. Indeed, transgenic mice, with systemic
over expression of rHu-EPO, were observed; they presented
hematocrit levels above 80% and developed longer strokes,
compared to their nontransgenic siblings, despite the high
expression levels of EPO in the brain [27].
In a previous report, we have demonstrated that
intranasal (IN) administration of Neuro-EPO proved to be
safe, reaches the brain in few minutes, does not stimulate
erythropoiesis after acute treatments, and shows eﬃcacy in
some rodent models of brain ischemia [28].
Neuroprotection is based in the pharmacological preven-
tion or limitation of an ischemic cascade progression form
in the brain tissue once it has begun [2]. The therapeutic
window is the time during which the drug may show eﬀec-
tiveness of and depends on the time course of biochemical
changes aﬀecting the treatment [29]. The treatment dosing
regimen and duration must be tailored to the biochemical
process to be aﬀected and must also take into account
diﬀerences in drug metabolism between species [30].
The objective of this work was both to determine
the dose response and the therapeutic window with the
Neuro-EPO IN application in the Mongolian gerbil focal
ischemia model, using evaluating variables such as viability,
neurologic deﬁcit score, spontaneous exploratory activity,
and histopathological status.
2.MaterialsandMethods
2.1. Animals. One hundred and forty male Mongolian
gerbils(12–15weeks;70–90g)wereprovidedbytheNational
Center for Laboratory Animal Breeding (CENPALAB) in
Havana, Cuba and were adapted to experimental conditions
for 7 days. The animals were maintained in controlled
environmental rooms at 22 ± 2◦C, relative humidity 55–
60%, light-dark cycle was 12h/12h, and there were 15–20
room air changes per hour.
All materials used to maintain the animals were auto-
claved at 121◦C for 20min. Food and water was provided
ad libitum. Each protocol was discussed and approved by
the Institutional Ethics Committee, considering that the
international standards established by CCAC [31] rHu-
EPO (ior CIM from CIMAB SA, and CIDEM Havana,
Cuba) and Neuro-EPO (not a commercial product; patent
PCT/cu2006/000001 Patent 20050138) were supplied by the
Center of Molecular Immunology (CIM) Havana, Cuba and
diluted in PBS (pH 7.0) at 0.15mM. Intranasal administra-
tion was performed essentially as described previously [32]
taking into account the established Guide to the Care and
Use of Experimental Animals. Immediately after surgery, the
gerbils were placed on their backs, and a total of 10µLo f
Neuro-EPO or a corresponding volume of vehicle solution
p e rg e r b i lw a sg i v e ni nn o s ed r o p so f( 5µL/drop) over a 1-
to 2-min period, alternating drops between the left and right
nares. The mouth and the opposite naris were closed during
the administration, so the drops could be naturally inhaled
high into the nasal cavity.
2.2. Surgical Procedure and Spontaneous Exploratory Activ-
ity Measurement. Gerbils were anesthetized with ketamine
atropine-diazepam (47; 0.02; and 5mg/kg, resp.). Lesions
were performed according to Butterﬁeld and McGraw’s
method[33].Brieﬂy,therightcommoncarotidartery(CCA)
was isolated and double-ligated using silk 5-0 suture and
was sectioned with surgical microscissors. In the controlled
operated animals, the artery was only isolated.
Twenty-four hours after unilateral permanent ischemia,
the appearance of the following clinical signs of infarction
was assessed: palpebral ptosis, bristling, loss of tone and
reﬂexes in the four limbs, postural asymmetry, rolling or
circling, and death. Each sign was scored separately. The
sum of scores creates a general neurological score for each
animal. The clinical signs of brain infarction were assessed
as previously established [34]. In brief, each animal was
evaluated to determine its neurological state according to a
scale (with a maximum of 30 and a minimum of 0) [34].
Gerbils were placed in the center of a round open
ﬁeld (30cm diameter and 25cm height). “Rearing” was
considered as standing straight up on the hind limbs and
tail, until the animal returned any forelimb to the ﬂoor or
touched the open ﬁeld wall with any forelimb. Neither a
subsequent straight after a rearing without reaching the ﬂoor
with any forepaw nor kangaroo-like posture was considered.The Scientiﬁc World Journal 3
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Figure 1: Percent of survival in ischemia model in Mongolian
gerbil, evaluating diﬀerent doses of intranasal formulation of
Neuro-EPO ∗(P<0.01); ∗∗(P,0.02) indicate signiﬁcant diﬀerence
in Kaplan Miller Test respect with vehicle (n = 35 per group).
Exploratory activity was determined by the rearing counted
at 3, 6, and 9min in the open ﬁeld. An average of the total
rearingcountswascalculatedforeachgroup,renderingthree
dots per trial. Dots were plotted, and the line obtained by
the minimal square method was calculated and considered
as the habituation curve. The slope of the habituation curve
was used to characterize the animal’s state.
2.3. Experimental Animals Groups. The distribution of the
experimental groups to study dose. (In each group n was 35
animals.)
(i) Control up (false injured).
(ii) Injured group with application of the vehicle
(placebo).
(iii) Ischemic Group treated with Neuro-EPO in a
low dose, 0.5mg/mL of Neuro-EPO concentration
(24.9UI every 8 hours for 4 days).
(iv) Ischemic Group treated with Neuro-EPO in a
mediumdose,1mg/mLofNeuro-EPOconcentration
(249.4UI every 8 hours for 4 days).
(v) Ischemic Group treated with Neuro-EPO in a high
dose, 2mg/mL of Neuro-EPO concentration (2
499.4UI every 8 hours for 4 days).
We assessed survival, neurological status, and sponta-
neous exploratory activity at 0 and 7 days. The histological
study, to evaluate the eﬀect of the drug on the tissue, was
performedatthedosewherethebestbehavioralperformance
was obtained.
The distribution of the experimental groups to study the
therapeutic window (treated with Neuro-EPO in a medium
dose of 1mg/mL concentration (249.4UI every 8 hours for 4
days)) in each group n was 35 animals.
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Figure 2: Clinical signs of stroke at 24h of permanent occlusion
of the right common carotid in the Mongolian gerbil, evaluating
diﬀerent doses of the intranasal formulation of Neuro-EPO.
Numbers indicate signiﬁcant diﬀerence between bars in the U test
of Mann and Whitney in respect with vehicle. (n = 35 per group).
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Figure 3: Values of slopes of the curve of room in the open ﬁeld
test, the day before and 7 days after surgery using diﬀerent dosages
of Neuro-EPO IN. Bars represented means ± standard deviation. P
values in the Wilcoxon test. The comparison was carried out in each
group among the day 0 and 7 days later. (n = 35 per group).
(i) Control group (false injured).
(ii) Ischemic Group with application of vehicle IN
(placebo).
(iii) Ischemic Group with Neuro-EPO application IN im-
mediately after injury.
(iv) Ischemic Group with Neuro-EPO application IN
starting at 6 hours after injury.
(v) Ischemic Group with Neuro-EPO application IN
starting 12 hours after injury.
(vi) Ischemic Group with Neuro-EPO application IN
starting 18 hours after injury.
2.4. Tissue Preparation
2.4.1. Histology. Gerbils were anesthetized for cardiac perfu-
sion. Each animal was perfused with 20mL of saline solution4 The Scientiﬁc World Journal
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Figure 4: Model of focal ischemia. Dorsal hippocampus. Causes brain ischemia in the hippocampus at 7 days after occlusion (B, E, H).
The Neuro-EPO protects the dorsal hippocampal CA3 sector in this model (C, I) and does not protect CA1 (F). H-E. A, B, C: Panoramic
view. Arrow: conservation of CA3 neurons. D, E, F: Dorsal hippocampal CA1 sector. Arrows withdrawn neurons with pyknotic nuclei and
eosinophilic cytoplasm. G, H, I Sector CA3 of the hippocampus. Arrowheads in E, F, and H macrophages with vacuolated cytoplasm.
a n dﬁ x e dw i t h6 0m Lo f4 %b u ﬀered formaldehyde solution,
pH 7.0. Brains were carefully removed and postﬁxed in the
same solution for several days. Fixed brains were dehydrated
and embedded in paraﬃn. Serial coronal sections of 8-µm
widthwereobtained.Sectionswerestainedwithhematoxylin
eosin and described using light microscopy.
2.4.2. Quantitative Morphological Analysis. Preparations
containing dorsal hippocampus (from 1.3 to 1.6 after
Bregma), according to the atlas by Loskota et al. [30],
were used. Observers were blind to the preparation origin.
Pictures of 400 times magnifying power were digitized and
processedbytheImageJprogram(http://rsb.info.nih.gov/ij/,
NIH). The area of hippocampus CA1 pyramidal layer was
measured, subtracting the area occupied by pyknotic cells.
Then, the normal remaining area of CA1 subﬁelds was
determined.
2.4.3. Statistical Analysis. The log rank test using GraphPad
Prism 4 to evaluate survival percentage for the three treated
groups and control was employed. Frequencies of clinical
signs and rearing counts were analyzed employing the Chi-
square independence test. The Mann-Whitney U test was
used for the comparison between the control and other
groups of neurological score rearing counts, slope, and
remaining CA1 area. The Wilcoxon matched pair test was
used for comparisons between hemispheres. For correlations
between morphological and functional variables, the Spear-
man’s rank correlation coeﬃcient was used. The statistical
analysis was carried out according to the Microsoft STATIS-
TICA version 6.0 program. In all, a level of signiﬁcance of
P<0.05 was accepted.
3. Results
Previous studies have shown that IN Neuro-EPO had
neuroprotective eﬀect in a similar ischemia animal model
[35]. Percent of viability was evaluated at three diﬀerent
doses of IN Neuro-EPO. The best results were detected at
24.9 and 249.4UI both signiﬁcantly higher when compared
with the control group. The dose that showed the best
percent of viability (67%) when was compared with theThe Scientiﬁc World Journal 5
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Figure 5: Model of focal ischemia. Parietal and temporal cortex. Unilateral ischemia produces infarction in the parietal cortices (B) and
temporal (E, H, K). The Neuro-EPO rescues neurons in the temporal cortex (F, I, L). H-E. A, B, C: Panoramic view of the parietal cortex.
hc: hippocampus; cc: corpus callosum; VL: lateral ventricle. D, E, F: A panoramic view of the temporal cortex. G, H, I: outer layers of the
temporal cortex. H: Loss of the neural elements with holes. I: looks like the control. J, K, L: deeper layers of the temporal cortex. K: Loss of
the neural elements with holes. L: looks like the control.
injured group treated with IN vehicle was the 249.4UI
(Figure 1).
The only dose for IN Neuro-EPO that showed a signiﬁ-
cant eﬀect on the neurological score (Figure 2)w i t hr e s p e c t
to the vehicle was the median dose of (249.4UI).
In the open-ﬁeld behavioral test to measure learning at
7d a y s( Figure 3) ischemic animals treated with Neuro-EPO
in the medium (249.4UI) and low (24.9UI) doses, a pattern
of habituation similar to controls was shown. The animals in
the vehicle-treated group showed poorer learning. This loss
of habituation is interpreted as the inability to recognize the
place already explored before carotid occlusion.
Ischemic animals treated with Neuro-EPO in the
medium dose (249.4UI) showed no neuroprotective eﬀects
in the CA1 region of the hippocampus; this is corroborated
with the study of neuronal densities. This area of the6 The Scientiﬁc World Journal
Control Ischemic + V in Ischemic + Tto neuro-EPO in
Figure 6: Model of focal ischemia thalamus. Unilateral ischemia produces large clusters of macrophages in the nuclei of the thalamus (B, E,
H). The thalamus damage decreases with Neuro-EPO in (C, F, I). H-E. A, B, C: Panoramic view. Arrow: focus of macrophages. VL: lateral
ventricle; hc: hippocampus. D, E, F: ×400 thalamus. E: Focus of macrophages. F: Control-like appearance. G, H, I: Thalamus x1000. H:
Macrophage with vacuolated cytoplasm (arrowhead), macrophage in mitosis (asterisk). I: Looks like the control.
hippocampus is one of the most sensitive to ischemia, and
the neuroprotective eﬀectof any drug wouldhave less chance
to be evidenced than less vulnerable areas. The histological
involvement was minor in the areas of CA3, cortex, and
thalamic nuclei in animals treated with Neuro-EPO as
illustrated in Figures 4, 5,a n d6.
Arteriesarenotfrequentlyaﬀectedinischemicinjury,are
on the periphery of the infarct, and supply these structures
where neuroprotection was observed. In this group, there
was only light damage in the CA1 and CA2 regions of the
hippocampus.
Seven days after ischemia, the histological damage
decreased in the above areas. The animals in the vehicle-
treated group showed necrosis of the temporal and parietal
cortices, hippocampus, thalamus, and caudate putamen,
loss of CA1 pyramidal neurons and cognitive impairment.
Infarction areas in the hemisphere ipsilateral to carotid
occlusion in the animals treated with the vehicle were
observed. On the contrary, these negative neurologic eﬀects
were reduced in animals treated with IN Neuro-EPO. The
results of this work constitute an indirect evidence of the
passage of Neuro-EPO to the CNS through the nasal cavity.
Hippocampal CA1 pyramidal neurons showed that
pyknotic, retracted, and acidophilic cytoplasm was observed
(Figure 4). In the infarcted area, granule-fatty corpuscles
(macrophages) ﬁlled with breakdown products of myelin,
wereobserved.Figure 7clearlyillustratesmacrophages,some
binucleate and mitotic processes. All these ﬁndings are
characteristic, and they have been described by other authors
in the ischemia model in injured animals [15, 36, 37].
To determine the therapeutic window, groups of animals
began receiving treatment with IN Neuro-EPO immediately
aftersurgeryat0,6,and12hours.Thesethreegroupsshowed
a greater survival at 7 days after occlusion, when compared
with the groups that received vehicle (Figure 8).
Thecomparisonbetweenthevaluesofoutstandingopen-
ﬁeld test in the control group not subjected to ischemia
showed signiﬁcantly more negative values in the second
determination, indicating a faster decline of the steep at
that time (Figure 9). Similar result was observed in theThe Scientiﬁc World Journal 7
Figure 7: Macrophages in ischemic animals. A: Binucleate macrophages in the corpus callosum. H-E. B: Macrophages in mitosis in the
corpus callosum. H-E. C: Macrophages in caudate putamen. Luxol fast blue y PAS. D: Macrophages near the lateral ventricle. Luxol fast blue
y PAS. E: Macrophages with vacuolated cytoplasm in mitosis (asterisk) in thalamus. H-E. Model of focal ischemia. Macrophages (arrows) in
several brain regions of ischemic animals.
groups treated with Neuro-EPO for 4 days, whether they
were treated immediately or at 6, 12, or 18 hours after
occlusion. However, vehicle-treated animals showed similar
slopes within 7 days of ischemia.
Initiating treatment with the IN N e u r o - E P Oa t0 ,6 ,1 2 ,
and 18 hours after the ischemic lesion showed eﬀectiveness
on the open ﬁeld test, when compared with the vehicle
(Figure 10).
Neuro-EPO protects the dorsal hippocampus CA3 sector
in the focal ischemia model (Figure 11). In the ischemic
group animals treated with vehicle, an infarct area was
observed in the hemisphere ipsilateral to carotid occlusion.
Stroke area was identiﬁed by the death of most of the
cellular elements, demyelination, presence of cellular debris,
and partially empty areas. The lesion zone extended to all
regions of the hippocampus (including much of the dentate8 The Scientiﬁc World Journal
10
20
30
40
50
60
70
80
90
100
110
(P)
S
u
r
v
i
v
a
l
(
%
)
 
0.0004 0.02 0.008 0.3 0.03
C V 0 h 6 h 12 h 18 h
     Control/vehicle and treatment application time
Figure 8: After 7 days of models of focal ischemia. P = Signiﬁcance
with regard to vehicle, indicating a signiﬁcant diﬀerence in the U
test of Mann and Whitney. (n = 35 per group). Dose Neuro-EPO
IN 249.4UI.
0
2
4
6
8
10
12
14
16
18
20
After
Before
C V 0 h 6 h 12 h 18 h
     Control/vehicle and treatment application time
V
a
l
u
e
 
o
f
 
s
l
o
p
e
s
Figure 9: Values slope the day before and 7 days after models of
focal ischemia. P values in paired rank test of Wilcoxon. (n = 35 per
group) Dose Neuro-EPO IN 249.4UI.
gyrus) the parietal and temporal cortex, in the thalamic
nuclei and caudate putamen. At 6 hours, the treated animals
showed no histological damage in either group. In the
CA3 area hippocampal pyramidal neurons showed pyknotic,
retracted, and acidophilic cytoplasm at 18 hours, evidencing
improvement in those treated with EPO.
4. Discussion
The focal ischemia model by carotid artery occlusion in
Mongolian gerbils has been used to study the pathophysiol-
ogy of focal cerebral ischemia and the evaluation of potential
neuroprotective agents [38–40]. The mortality in this model
reﬂects the severity of the injury, and it is an important
variable in assessing drugs for the treatment of ischemia. In
this model, mortality rates between 30 and 40% at 24 and 48
hours after ischemia have been reported [41, 42]. This allows
us to suggest that these animals have a cognitive dysfunction
induced by ischemia, which aﬀected their learning and
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Figure 10: Slope values 7 days after of models of focal ischemia.
P values of comparison against the vehicle group by the U test
of Mann and Whitney. (n = 35 per group). Dose Neuro-EPO IN
249.4UI.
short-term memory [43]. In ischemic animals histological
lesions found are similar to those described in other studies
[44, 45]. Whereas ischemic animals showed no histological
injury in neurological impairment and cognitive ability; one
might think that the brain tissue, albeit with HE staining was
observed intact, was biochemically committed [46].
It has been reported that in the penumbra area there is
s t i l lac e r e b r a lb r a i nﬂ u i d( C B F )b e l o wn o r m a ll e v e l s[ 47].
Perhaps the arrival of Neuro-EPO to this penumbra region
protected these cells against excitotoxicity and phenomena
such as apoptosis. It has also been shown that rHu-EPO
and its derivatives stimulate the process of angiogenesis and
neurogenesis, providing a favorable microenvironment for
neural plasticity during stroke recovery [48–50].
Comparison of the treated and untreated injured groups
was carried out to assess the learning capacity linked to
short-term memory, dependent on synaptic transmission
and neuromodulation. According to our results, treatment
with Neuro-EPO IN equally protects against the occurrence
of dysfunction in learning and short-term memory, even
starting the treatment at 18 hours, suggesting a neuropro-
tective eﬀect on this functional impairment.
The eﬀects observed in the preservation of habituation
behavior in animals, where treatment started as late as 18
hours, suggests the inhibition of processes such as neuronal
apoptosis in brain regions associated with that behavior,
and the expression of neurotrophic properties that enhance
neuronal function. Apoptosis requires the expression of
eﬀector proteins in the longer term; therefore, it could be
interfered with at 18 hours after onset of ischemia by Neuro-
molecules such as EPO, which can induce the expression of
antiapoptotic proteins [48]. All these mechanisms strongly
point in favor of the process of neuroplasticity that may be
induced by Neuro-EPO in the damaged brain.
TheHippocampalCA1regionshowssevereneuronalloss
in 85–95% of the gerbils after 7 days of occlusion. It has been
shown that neuronal death in the case of ischemia is selective
for neuronal groups; besides, neuronal death does not occur
either in the same manner or at the same time. There are cell
groups such as the vulnerable Hippocampal CA1 pyramidal
cells that begin to die from the ﬁrst 5 minutes after ischemiaThe Scientiﬁc World Journal 9
Figure 11: Hematoxylin-eosin. The Neuro-EPO protects the dorsal hippocampal CA3 sector in the focal ischemia model, (C, D, E). Bar
100µmA:dorsalhippocampalCA3sectorincontrol.B:Arrowswithdrawnneuronswithpyknoticnucleiandeosinophiliccytoplasmanimals
treated with vehicle. C, D, E: dorsal hippocampal CA3 without injury starting treatment with Neuro-EPO intranasal at immediately, 6 hours
at 12 hours, respectively. F: Dorsal hippocampal CA3 sector starting treatment at 18 hours. Arrows withdrawn neurons with pyknotic nuclei
and eosinophilic cytoplasm.
and others such as the CA2 and CA3 cells, which the process
of neuronal death can take about 6 to 12 hours to begin [51].
The results suggest that despite the fact that permanent
occlusion did not induce infarction in all animals, as
described in the literature, there is a decrease in cerebral
blood ﬂow that could induce damage, which becomes
evident in the chronic phase, when secondary degeneration
processes have already taken place [52, 53]. It has been
reported that in animals without histological lesions there is
achronicstateofhypoperfusioninthehemisphereipsilateral
to the occlusion, where the blood ﬂow is above the threshold
of ischemia, but below normal levels [54].
In the adult’s brain, the system EPO/EPO-R seems
to be in a quiescent state. The role of EPO receptor in
its neuroprotective action is present time topic, but it is
not aim of this scientiﬁc research. Indeed, a very recent
paper showed a neuroprotective eﬀect of EPO in an EPO-
R knock out stroke animal model, which suggests that
EPO’s neuroprotective eﬀect is not only through the EPO-
R receptor; it probably involves the regulation of CBF [55].
On the other hand, Sanchez et al. 2009 [56] reported that
an optimal neuroprotectant by erythropoietin requires an
elevated expression of its receptor in neurons. It was also
conﬁrmed in our previous work [57].
The expression of the system EPO/EPO-R in the brain,
andspeciﬁcallyinareaswithneuronsthatareveryvulnerable
to ischemic insult (hippocampus and cerebral cortex) has
been recently demonstrated [58]. The diﬀerential stimula-
tion of the EPO system/EPO-R rapidly after hypoxia empha-
sizes its role as a physiological mechanism of protection in
the mammalian brain [59].
The cognitive impairment observed in the open ﬁeld test
can be attributed to damage in the hippocampus, cerebral
cortex, and thalamus [35]. These observed structures that
were neuroprotectant are supplied by arteries that are not
frequently aﬀected in ischemic injury. These arteries are
on the periphery of the infarct, which appears likely in
the ﬁrst hours after occlusion. In this group, there was
only light damage in the CA1 and CA2 regions of the
hippocampus.
The intranasal route oﬀers the possibility of administer-
ing lower doses than those required intravenously [20, 28,
60]. In addition, it allows chronic, acute, and safe treatment;
which is a necessary condition that a neuroprotectant must
have against the neurodegenerative illnesses.
It has been shown that treatment with Neuro-EPO
immediately after occlusion in this model, is eﬀective in
reducing mortality in both sexes [32]. Previous experiments
have shown that gerbils that develop clinical ischemia signs
have a high incidence of pathological events in the hemi-
sphere for 24 hours after surgery and die within 72h [54].
One of the limitations of the neuroprotective agents
assessment, in preclinical and clinical, is the therapeutic
time window, in which the agent is able to interfere with
the processes leading to cell death and the consequent
impairment of brain function due to ischemia [58, 61]. The
intravenous administration of rHu-EPO in a model of MCA
occlusion in rat-neuroprotective eﬀects extended up to 6
hours after injury [62]. This therapeutic window is twice
that of tissue plasminogen activator (tPA), and the only drug
treatment currently approved to treat the acute ischemic
stroke and thrombosis [59, 63, 64].10 The Scientiﬁc World Journal
It has been shown that the expression of mRNA for the
formation of the molecule of EPO and its receptor takes
between 2 and 4 hours after the ischemic insult. Thus,
protecting endogenous small insults solves the problem, but
when the ﬂow decreases to a critical level, it is necessary
to exogenous EPO administration to assist the equilibrium
establishment that involves minimizing the damage caused
by the ischemic cascade [65].
It has been compared in recent studies by Tsai et al. [66]
and Wang et al. [67] and Villa et al. [68] that the derivative of
the rHu-carbamylated EPO (CEPO) has a wide therapeutic
window in focal ischemia model in rats; it also has not the
eﬀect in the stimulation of the platelets production.
In general, the results have corroborated that in Neuro-
EPO has neuroprotective properties similar to asialic and
carbamylated derivatives of rHu-EPO, and the intranasal
administration seems to be related to a therapeutic window
period as large as 12h for the acute manifestations of
ischemia in this model, or 18 hours for chronic manifes-
tations [7, 37, 69–72]. Indeed, Neuro/EPO IN showed the
highest therapeutic window reported in preclinical stroke
studies till now.
The fundamental ﬁnding of this study has shown that
the therapeutic window of the Neuro-EPO IN is up to
12h, which gives this molecule very beneﬁcial characteristics
in future clinical application [69]. In medical practice, the
therapeutic window is a crucial factor that determines the
eﬃcacy of neuroprotection [73].
In summary, the dose eﬀect and the average dose used
Neuro-EPO(249.4UI/10µL/every8hoursfor4days)proved
to be valid indicators of viability, neurological status, and
spontaneous exploratory activity since it is signiﬁcantly
lower than the reported for the systemically use of the
rHu-EPO as neuroprotectant. In addition to that, up to
12h window for Neuro-EPO IN administration as a can-
didate for neuroprotection in acute brain ischemia is very
positive quality. These solid results may support the way
of this molecule to the clinical trail for the acute stroke
treatment.
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